|
 
- 现金
- 176 元
- 精华
- 0
- 帖子
- 112
- 注册时间
- 2015-5-14
- 最后登录
- 2016-11-12
|
本帖最后由 disan 于 2015-6-20 22:21 编辑
Current treatment options include interferon, which is difficult to use due to highly disruptive side effects, and nucleotide or nucleoside analogues, referred to collectively as NUCs. The best NUCs are very good at suppressing viremia, the production and release of new viral particles, but are not capable of directly suppressing the production and release of viral proteins including s-antigen and e-antigen. Neither interferon nor NUCs provide meaningful rates of functional cure.
ARC-520 uses a different mechanism than NUCs
RNAi in general, and the siRNAs in ARC-520 specifically, act in a fundamentally different way than NUCs. These siRNAs intervene at the mRNA level, upstream of where nucleotide and nucleoside analogues act, and have been shown to deeply knock down all HBV gene products, including proteins and the viral intermediates necessary to produce viral DNA. Many experts in the field believe that knocking down key viral antigens may revive the host adaptive immune response and potentially achieve a functional cure. |
|
楼主: newchinabok
发表于 2015-6-20 17:29
